Analytical Data
-
Gene name
FOXN1
- Application
-
Alternative Names
(Winged-helix transcription factor nude)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15353
-
Expression Region
1-648aa
-
Molecular Weight
76.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FOXN1 (Forkhead box N1) is a crucial transcription factor implicated in the development and function of thymic epithelial cells, which are essential for T-cell maturation and immune system function. Research on FOXN1 has gained significance due to its role in immunodeficiency disorders and its potential implications in autoimmune diseases and cancer. Deficiencies or mutations in FOXN1 can lead to severe combined immunodeficiency (SCID) and athymic conditions, highlighting the protein's importance in T-cell development. Recent studies have focused on the recombinant expression of FOXN1 to better understand its structure-function relationship and to explore therapeutic avenues for conditions associated with FOXN1 dysfunction. By producing and characterizing FOXN1 as a recombinant protein, researchers aim to elucidate its molecular interactions, regulatory mechanisms, and pathways involved in thymus development. This research is pivotal for developing potential interventions, including gene therapy and regenerative medicine strategies, to restore immune function in affected individuals. Overall, the investigation of FOXN1 recombinant protein serves as a foundation for advancing our understanding of thymic biology and enhancing therapeutic approaches for related immunological disorders.
